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(Main text: 2548 words) 
Academic research and industrial innovation are both integral drivers of the discovery process 
that eventually culminates in innovative therapies and new medicines1. Academic research is 
conducted in university, hospital or research center campuses furnished with several degrees of 
freedom, but also hampered by funding constraints. Industrial research in large companies tends 
to resonate more with the rigid organizational blueprint and internal regulatory control which 
spans the entire spectrum of corporate structure. Start-ups are somewhere in the middle; they 
may have components of both academic and industrial origin, but in theory their major advantage 
is that they can avoid both the funding constraints of academia and the rigid organizational 
constraints of large companies.  
Academically-led innovation typically thrives on competitive funding from public agencies and 
may not be easy to invest a lot of funds on high-risk ideas. Large companies are also increasingly 
risk-averse in trying to invest in innovation and leave much of this early, high failure rate step to 
start-ups.   
The reliance of research on public funding should invoke a strong sense of accountability, 
primarily towards the contributing taxpayers or charity donors (i.e., the broader public). In turn, 
this research accountability should be reflected in a high level of data integrity and transparency, 
which is mainly achieved through several rounds of review by expert scientists before the 
described research product (e.g. drug target/candidate) can reach the public domain in peer-
reviewed publications. Taxpayers should know that their hard-earned contributions are being 
invested in work that gets validated by rigorous peer review and also may eventually help 
patients. These opportunities can only be nourished by robust scientific evidence and peer-
validated technologies in developing innovative patient treatments 2.  Naturally, similar 
requirements regarding transparency and data integrity should also apply when such research is 
partially or fully conducted by start-up companies, regardless of whether academic or other (e.g. 
clinical) investigators are involved.  
Rigorous scientific scrutiny at all steps of the discovery process is essential, regardless of whether 
this innovation is generated in university laboratories or biotech cubicles. With great clinical 
impact comes even greater responsibility to communicate and engage with the scientific 
community through clear and irrefutable underpinning data. Data validation by means of peer 
reviewed publications should also apply to medicinal products discovered and clinically developed 
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entirely within industrial venues. The investor-driven funding that enables start-up and 
biopharma research to advance its pipeline of products through clinical development should not 
create impediments in the way of maintaining data transparency and open access to research. 
Industry-based research should not only be communicated between company executives, 
investors, stock brokers or venture capitalists through vaguely formulated press releases with no 
primary data or independently validated conclusions. Instead, its underpinning data should be 
made publicly available to allow for evaluation of its validity and the long-term consequences of 
its conclusions.  
The exposure of some types of industrial research results to rigorous peer review is lagging behind 
that of their academic counterparts. This may be a more prominent issue for research covering 
the early stages of the discovery to clinical validation pipeline, usually conducted by smaller 
companies (including start-ups), than for larger biopharma working further down the pipeline. 
The lack of peer-reviewed publications from small companies and start-ups has been attributed 
to many factors, among which corporate intellectual property protection from competition holds 
a prominent place, especially for early stage research 3. Most major pharmaceutical companies, 
at critical checkpoints of technology development, engage in peer review of their technologies or 
products. However, it is the aspiring startups and biotech small- or medium-sized enterprises that 
tend to rely more on media hype than on actual scientific evidence, in an effort to direct, as early 
as possible, investor funding towards their products 4. This evolving and increasingly accepted 
practice of shielding scientifically important corporate data is at odds with the standards of 
research accountability through peer evaluation, data transparency, research integrity and finally, 
data openness 5.  
Placing these general considerations into perspective, Cristea and colleagues recently evaluated 
the lack of peer-reviewed evidence from healthcare unicorns 6; that is, biotech startups with 
promising technologies and market valuations that exceed the 1 billion threshold.  Many startups 
had secured exceedingly high market valuations despite a lack of peer-reviewed publications to 
support their market-directed innovations. To further probe the extent of this stealth mode of 
research and its potential adverse repercussions in the healthcare industry 4 , we decided to apply 
this analysis to the complement system drug space and investigate whether similarly obscure 
corporate practices fuel ͚stealth͛ innovation among startups active in the clinical development of 
complement therapeutics.  
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We should stress that most of the clinical indications currently targeted in the complement drug 
space are designated as rare or orphan diseases 7. Therefore, the small numbers of treatable 
patients and the projected low financial return of orphan medicines, impose commercial risks that 
have been counterbalanced by the enactment of special legislation (e.g. US Orphan Drug Act). 
These offer several incentives to companies developing orphan medicinal products, such as 
market exclusivity rights and expedited regulatory approval and oversight during clinical 
development 8. Today, complement drug discovery has been thrust into the limelight of the 
healthcare industry with more than 20 candidate drugs advancing through clinical development  
(i.e., Phase II/III) for a wide spectrum of complement-mediated diseases 9,10,11. A growing number 
of startups have engaged in developing complement-targeted drug candidates, alongside 
established pharmaceutical companies that have also initiated complement drug programs within 
their highly diversified portfolios 9. In exploiting the rekindled interest of the biopharma industry 
to target this innate immune system, several startups have managed to acquire  exceedingly high 
market valuations that likely reflect mounting investoƌs͛ iŶteƌest iŶ  ǁhat appeaƌs to ďe  a ƌapidlǇ 
evolving field of commercial, not only clinical, opportunity. Yet, is this interest of the capital 
market firmly rooted in scientific facts or is it driven instead by media hype? 
To gain insight into the extent to which complement-dedicated startups with high market 
valuations have engaged in peer review validation of their products, we conducted a literature 
search for publications co-authored by these companies. Scopus (Elsevier) was selected as our 
literature search engine and our retrievals included original research articles, editorials and 
reviews. The ͚affiliation name͛ of the company was combined in a search for documents including 
the teƌŵ ͞ĐoŵpleŵeŶt͛ iŶ the title/aďstƌaĐt/keywords and also in extracted meta data (all fields) 
associated with the document in question. All publications were cross-validated manually for the 
true association of their content (abstract) to complement research or complement-targeted 
therapeutics, excluding usage of the term ͚ĐoŵpleŵeŶt͛ in its grammatical sense. We chose to 
include in our analysis 17 companies with clinical-stage complement drug leads disclosed through 
their official websites, focusing on programs whose documentation in the literature commenced 
since 2003 and on complement innovators with consistent commitment to this drug space 9. We 
focused only on start-ups and thus large global healthcare companies with recently initiated 
complement drug programs were not included in this analysis. Our search yielded quite striking 
results with regard to a group of startups/medium-sized enterprises which are either publicly 
listed on the stock exchange or privately held (Figure 1)  
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As shown, companies with the highest market valuation tend to make less of their research results 
accessible to the scientific community through peer-reviewed publications. With regard to 
publicly listed companies with known market valuation, with few exceptions (such as Omeros and 
the Germany-based InflaRx which both have a notable publication record), there is an inversely 
proportional relationship between market valuation and peer-validated research output (Fig. 1). 
This observation should be considered with some caution given the relatively small number of 
companies assessed. However, it not only resonates with the main message conveyed by the 
perspective article of Cristea et al., but also raises awareness about a ͚stealth͛ research culture 
that may have infiltrated the complement drug discovery space, disengaging industrial innovation 
from evidence-based scientific documentation.  
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It should ďe Ŷoted that IŶFla‘ǆ͛s iŵpƌessiǀelǇ high ŵaƌket Đap of ϭ.ϬϱB declined precipitously 
under the pressure of the recently released (June 5th, 2019) negative results from its multi-center 
Phase II study evaluating the efficacy of its lead product, the monoclonal anti-C5a antibody IFX-1, 
in patients with the rare skin disorder hidradenitis suppurativa (HS) 12. In the wake of this news 
the ĐoŵpaŶǇ͛s stoĐk pluŵŵeted, losing more than 90% of its original value, with the current 
market cap of the company reduced to 75M (https://finance.yahoo.com/quote/ifrx?ltr=1) (Fig. 
1). Interestingly, while the company had published several papers on its main product, IFX-1, the 
decision to advance this candidate to trials for HS in particular was based on weak evidence, a 
Figure 1. Market valuation of complement-related drug development companies vs research output (peer-reviewed 
publications of company-sponsored research) validating their complement-related technology or drug candidate. All 
market caps have been retrieved through Yahoo͛s finance search engine: https://finance.yahoo.com/ and converted 
for uniformity to USD based on currency exchange rates, as of 07/30/19. Our analysis has included five privately held 
companies (not listed on stock exchange). These are Amyndas, Annexon, Adienne, Alsonex and Hemera Biosciences. 
The valuation of these private companies was retrieved through the CBInsights platform and is available in the online 
supplement. For reasons of conformity market values for these companies are shown as zero in this graph. Publications 
refer to peer-reviewed papers (original research articles, reviews and editorials) ƌetƌieǀed thƌough Elseǀieƌ͛s “Đopus 
search engine. Conference presentations, conference proceedings or corporate presentations and 
investor/shareholder-oriented releases have been excluded from this analysis. All the primary data used for this 
aŶalǇsis, ǁith details oŶ eaĐh ĐoŵpaŶǇ͛s puďliĐatioŶ ƌeĐoƌd aŶd related citations are available online as a supplement. 
The year in which each company was founded is depicted on top of the respective bar. The asterisks denote that these 
companies clinically develop different versions of the same C3- inhibitory peptide, compstatin. The dashed bar indicates 
the market cap of InFlaRx before the announcement of the failure of IFX-1 in the Phase II trials in hidradenitis 
suppurativa.  
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single recent publication with limited translational data, perhaps insufficient to support a full 
commitment to clinical trials for HS 13. The case of InflaRx further illustrates that occasionally a 
ĐoŵďiŶatioŶ of ŵedia hǇpe, iŶǀestoƌs͛ iŵpatieŶĐe, loosely connected preclinical evidence and 
lack of sufficient peer-reviewed evidence for the targeted indication can drive corporate decisions 
into ͚murky waters͛.  Of note, the market fall of InflaRx had parallel repercussions on the stock 
price of another complement-related biotech company, Chemocentryx, which develops an orally 
available C5aR1 antagonist that prevents activation of the same effector pathway in complement-
mediated inflammatory disorders. Of note, Chemocentryx stock value dropped sharply by 22% 
within two days following the announcement of the InflaRx trial results (data available in online 
supplement). It is ǁoƌth ŵeŶtioŶiŶg that CheŵoĐeŶtƌǇǆ͛s Đandidate drug, Avacopan, is currently 
in Phase III trials of ANCA-associated vasculitis and results are eagerly awaited in view of these 
developments 9. 
The peer-reviewed maturity of a technology (i.e., pharmacology/biological efficacy of a drug 
candidate) is not necessarily reflected in the market valuation of the respective company. There 
is a considerable ƌisk of lettiŶg iŶǀestoƌs͛ deĐisioŶs aŶd ŵaƌket ďias skeǁ the direction of clinical 
research, irrespective of which drug candidate the evidence base suggests might be most 
efficacious. For instance, several highly valued public companies have advanced their lead 
compounds into late-stage clinical development without having released in the literature any 
causative/mechanistic or preclinical evidence to support the feasibility of their clinical program. 
For example, Omeros Corporation has advanced its lead compound, the anti-MASP2 inhibitor 
OMS721, into two Phase III  trials, in IgA nephropathy and aHUS respectively, without any relevant 
publication supporting proof of concept in these indications 9. On the contrary, all Omeros-
affiliated publications support the development of anti-MASP2 inhibitors as treatment options for 
cerebral, myocardial or gastrointestinal ischemia-reperfusion injury (data available in the online 
supplement).    Apellis Pharmaceuticals, a public company advancing C3-targeted inhibitors 
through Phase II/III trials, has already achieved an impressively high market valuation of 
approximately $1.8B (Fig. 1), the highest among all of the complement-focused drug development 
companies, likely kindled by the release of non-peer-reviewed clinical results of ongoing trials. 
While clinically developing its lead drug candidate, a PEGylated compstatin–based C3 inhibitor 
APL-2, for several indications, Apellis has refrained from peer-reviewed publications, confining its 
research output to press releases, conference posters and corporate announcements about the 
status of ongoing clinical trials 9.  Similarly, Ra Pharmaceuticals, has taken its lead compound, 
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Zilucoplan/RA101495, to Phase III trials in patients with paroxysmal nocturnal hemoglobinuria, 
without any published peer-reviewed evidence corroborating or benchmarking their technology 
against the standard of care in this specific clinical indication 14.   
Our literature-based analysis was further extended to privately-held pharmaceutical companies 
developing complement therapeutics.  For instance, Amyndas is a recently established startup 
advancing 3rd and 4th generation compstatins through Phase II trials that have been 
communicated in the scientific literature with 9 co-authored publications (Fig. 1). Alsonex, a 
biotech company developing therapeutics for neurodegenerative diseases, offers another 
interesting example of how corporate innovation can gain leverage from academically-led 
research results. While its lead compound, ALS-205, has not been registered in any publication so 
far, its development gains traction from the prominent academic publication record of its 
equivalent, PMX-2059.  
Our analysis further points to the consequences of insufficiently validated research in a setting 
that appears to be heavily influenced ďǇ ŵedia hǇpe aŶd dispƌopoƌtioŶatelǇ high iŶǀestoƌs͛ 
expectations.   For example, the recent partnership of Zealand Pharma, a company with expertise 
in peptide-based therapeutics for metabolic diseases, with Alexion, the leading company in 
marketed complement therapeutics, for the joint development of C3-based inhibitors15, made the 
headlines of biotech news channels 15. While Zealand has a publication portfolio that supports its 
glucagon-like peptide-related technology, it has yet to publish any paper related to complement 
immunomodulatory peptides or C3 inhibition (see Fig. 1).  Lastly, the recent partnership of UK-
based Silence Therapeutics, a biotech with expertise in RNA interference technology, with 
Mallinckrodt Pharmaceuticals, to mutually develop their preclinical lead compound SLN500 as a 
C3-targeted RNAi therapeutic, was widely publicized in the media 16. Despite a potential return of 
approximately $2.0B in combined milestone payments and commercial royalties, Silence has yet 
to produce any peer-evaluated line of evidence as to how this compound can achieve sustainable 
C3 inhibition in a therapeutically relevant context. The recently rekindled interest of big 
biopharma in gene therapy platforms for the treatment of chronic diseases 17, along with the 
excessively high, multi-billion dollar buyouts announced for the acquisition of gene therapy 
startups by global healthcare leaders (e.g. ‘oĐhe͛s aŶŶouŶĐed aĐƋuisitioŶ of “paƌk TheƌapeutiĐs 
for $4.5B in February 2019) have evidently garnered a lot of momentum for such approaches, as 
yet unsupported by transparent, evidence-based science and data openness 18.  
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To gain insight into the overall impact of the peer-reviewed papers produced by complement 
startups we examined how many of the papers shown in Figure 1 have received more than 30 
citations in Scopus, as of 8/6/2019. We found that 14 out of a total 48 papers had more than 30 
citations each, covering a time period from the inception date of each company to present, 
indicating that almost 1/3 of the research output from these companies has garnered significant 
attention from peers (a complete record of citations retrieved per publication, per company, is 
provided in a supplementary file). 
We should caution that absolute number of publications is, of course, only a modest marker of 
the reliability of evidence. Also citation impact is only a modest marker of the extent of validation, 
let alone an indicator of the future potential of a drug under investigation. Despite clear 
limitations, the peer-review system is still regarded as the most reliable tool to evaluate scientific 
data. Nevertheless, it is important to examine peer-reviewed papers with a critical eye. 
Additionally, the inclination of both authors and editors to publish ͞positive͟, as opposed to 
͞negative͟ results, has created a bias in the literature with important implications in the field of 
clinical therapeutics. Peer-reviewed papers, even when well cited, may still be suboptimal, flawed, 
or largely irrelevant to the real translational value. An example illustrating the latter is AŶŶeǆoŶ͛s 
anti-C1q technology which, despite its sizeable impact in the literature (>560 citations, Scopus) 
has yet to overcome significant translational hurdles for clinical evaluation in neurodegenerative 
diseases.  
Lastly, the credibility and concrete scientific base of a startup͛s lead teĐhŶologǇ may also be 
reflected by the record of scientific achievements and broader impact of its founders. Retrieving 
a set of impact metrics for the co-founders of the 17 companies in Figure 1, we observed that only 
4 out of these 17 companies were founded on the expertise of leading scientists with a sizeable 
impact on the literature, as deduced by their H-indices and total citations, (H>50 and total 
citations>20,000 according to Scopus). Although we acknowledge that this aspect is not a 
mandatory condition for the clinical success of any drug lead, it does provide an interesting 
perspective as to how ͚thought leadeƌs͛ iŶ the field shape drug discovery efforts and become 
drivers of corporate innovation.  Scientific advisory boards are also important to guarantee field 
expertise. However, information on the membership and level of involvement of these boards is 
often lacking 6.  
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Concluding remarks and outlook  
The growing interest in complement therapeutics, as exemplified by a burgeoning pipeline of drug 
candidates currently in early or late-stage clinical development 9, has thrust complement drug 
discovery into the spotlight of biopharmaceutical research. At the same time, corporate data 
integrity and practices leading to scientific uncertainties are key issues that need to be dealt with 
in a transparent manner if these new therapeutics are to be translated into meaningful new 
therapies for patients. Despite a growing number of clinical trials being registered for the 
evaluation of complement-targeted drugs, peer-reviewed validation of new therapeutic concepts, 
targets and drug leads remains problematic, particularly in the case of startups that have secured 
large market valuations capitalizing on investor expectations and increased media attention. 
While we acknowledge that corporate innovation has to be protected through stringent IP 
policies, healthcare products that affeĐt patieŶts͛ liǀes, such as complement-targeting drugs, 
should undergo rigorous peer-reviewed validation before engaging sizeable resources and funds 
for clinical research and trials. 
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